

PUBLIKACJE 2018
Kliniki Chorób Zakaźnych i Hepatologii UMB
IF: 126,324; MNiSW: 537

- 1: Jarcuska P, Abdel-Razik A, **Flisiak R**, Singh RB. Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk. *Can J Gastroenterol Hepatol.* 2018: 7369314.
IF₂₀₁₈-1,714; MNiSW-20

- 2: Janczewska E, Zarębska-Michaluk D, Berak H, Piekarska A, Gietka A, Dybowska D, Mazur W, Belica-Wdowik T, Dobracki W, Tudrujek-Zdunek M, Deroń Z, Buczyńska I, Sitko M, Czauż-Andrzejuk A, Lorenc B, Białkowska-Warzecha J, Citko J, Laurans Ł, Jaroszewicz J, Socha Ł, Tronina O, Adamek B, Horban A, Halota W, Baka-Ćwierz B, Tomaszewicz K, Simon K, Garlicki A, Wawrzynowicz-Syczewska M, **Flisiak R**. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. *BMC Infect Dis.* 2018;18(1):580.
IF₂₀₁₈-2,565; MNiSW-30

- 3: Tomaszewicz K, **Flisiak R**, Halota W, Jaroszewicz J, Lebensztejn D, Lisik W, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tronina O. Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). *Clin Exp Hepatol.* 2018;4(3):153-157.
MNiSW-7

- 4: Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhatab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, **Flisiak R**, Chan HLY. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. *Dig Dis Sci.* 2018;63(12):3487-3497.
IF₂₀₁₈-2,937; MNiSW-25

- 5: Łapiński TW, Rogalska-Płońska M, Kowalczyk O, Kiśluk J, Zurnowska J, Nikliński J, **Flisiak R**. Significance of mutations in the region coding for NS3/4 protease in patients infected with HCV genotype 1b. *Adv Clin Exp Med.* 2018;27(11):1593-1600.
IF₂₀₁₈-1,227; MNiSW-15

- 6: **Flisiak R**, Janczewska E, Łucejko M, Karpińska E, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stepniewska K, Tomaszewicz K, Karwowska K, Simon K, Piekarska A, Tronina O, Tuchendler E, Garlicki A. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir ±ribavirin in the AMBER, real-world experience study. *J Viral Hepat.* 2018;25(11):1298-1305.
IF₂₀₁₈-4,016; MNiSW-35

- 7: **Flisiak R**, Jaroszewicz J, Łucejko M. siRNA drug development against hepatitis B virus infection. *Expert Opin Biol Ther.* 2018;18(6):609-617.
IF₂₀₁₈-3,585; MNiSW-30

- 8: Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, **Flisiak R**, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz

J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. *Clin Infect Dis*. 2018;67(7):1010-1017.

IF₂₀₁₈-9,055; MNiSW-45

9: Zarębska-Michaluk D, **Flisiak R**, Jaroszewicz J, Janczewska E, Czauż-Andrzejuk A, Berak H, Horban A, Staniaszek A, Gietka A, Tudrujek M, Tomasiewicz K, Dybowska D, Halota W, Piekarska A, Sitko M, Garlicki A, Orłowska I, Simon K, Belica-Wdowik T, Baka-Ćwierz B, Mazur W, Białkowska J, Socha Ł, Wawrzynowicz-Syczewska M, Laurans Ł, Deroń Z, Lorenc B, Dobracka B, Tronina O, Pawłowska M. Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? *J Interferon Cytokine Res*. 2018;38(2):93-100.

IF₂₀₁₈-1,774; MNiSW-25

10: Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, **Flisiak R**, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. *N Engl J Med*. 2018;378(4):354-369.

IF₂₀₁₈-70,670; MNiSW-50

11: Rogalska-Płońska M, Grzeszczuk A, Rogalski P, Łucejko M, **Flisiak R**. Metabolic syndrome in HIV infected adults in Poland. *Kardiol Pol*. 2018;76(3):548-553.

IF₂₀₁₈-1,674; MNiSW-15

12: **Flisiak R**, Zarębska-Michaluk D, Janczewska E, Staniaszek A, Gietka A, Mazur W, Tudrujek M, Tomasiewicz K, Belica-Wdowik T, Baka-Ćwierz B, Dybowska D, Halota W, Lorenc B, Sitko M, Garlicki A, Berak H, Horban A, Orłowska I, Simon K, Socha Ł, Wawrzynowicz-Syczewska M, Jaroszewicz J, Deroń Z, Czauż-Andrzejuk A, Citko J, Krygier R, Piekarska A, Laurans Ł, Dobracki W, Białkowska J, Tronina O, Pawłowska M. Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study. *J Viral Hepat*. 2018;25(6):661-669.

IF₂₀₁₈-4,016; MNiSW-35

13: Gudowska-Sawczuk M, Wrona A, Gruszewska E, Cylwik B, Panasiuk A, **Flisiak R**, Chrostek L. Serum level of interleukin-6 (IL-6) and N-terminal propeptide of procollagen type I (PINP) in patients with liver diseases. *Scand J Clin Lab Invest*. 2018;78(1-2):125-130.

IF₂₀₁₈-1,380; MNiSW-20

14: Łucejko M, **Flisiak R**. Quantitative measurement of HCV core antigen for management of interferon-free therapy in HCV-infected patients. *Antivir Ther*. 2018;23(2):149-156.

IF₂₀₁₈-2,305; MNiSW-35

15: Jelski W, Strumnik A, Orywal K, **Łapiński TW**, Swiderska M, Szmitkowski M. Activity of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in sera of patients with hepatitis C. *Arch Med Sci* 2018; 14, 2: 281–287.

IF₂₀₁₈-2,380; MNiSW-30

17: Jelski W, Wolszczak-Biedrzycka B, Zasiłowicz-Majewska E, Orywał K, **Łapiński TW**, Szmitkowski M. Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in the Serum of Patients with Non-alcoholic Fatty Liver Disease. *Anticancer Res.* 2018;38(7):4005-4009.

IF₂₀₁₈-1,935; MNiSW-20

18: Jelski W, Wolszczak-Biedrzycka B, Zasiłowicz-Majewska E, Orywał K, Piechota J, **Łapiński TW**, Bednarczyk M, Szmitkowski M. The Activity of Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase in the Sera of Patients with Autoimmune Hepatitis. *Clin Lab.* 2018;64(4):477-481.

IF₂₀₁₈-0,955; MNiSW-20

19: Łucejko M, Flisiak R. Effect of HCV core antigen and RNA clearance during therapy with direct acting antivirals on hepatic stiffness measured with shear wave elastography in patients with chronic viral hepatitis. *Applied Sciences* 2018; 8, 2: 198

IF₂₀₁₈-2,217; MNiSW-25

20) Parfieniuk-Kowerda A, Jaroszewicz J, Łapiński TW, Łucejko M, Maciaszek M, Świdorska M, Grzeszczuk A, Naumnik B, Rowiński M, Flisiak R. High prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders in eastern Poland. *Arch Med. Sci.* DOI: <https://doi.org/10.5114/aoms.2018.79958>

Online publish date: 2018/12/05

IF₂₀₁₈-2,380; MNiSW-30

21: Dorota Zarębska-Michaluk, Jerzy Jaroszewicz, E. Janczewska, Hanna Berak, Andrzej Horban, M. Sitko, A. Garlicki, B. Dobracka, Agnieszka Czauż-Andrzejuk, Dorota Dybowska, Waldemar Halota, M. Pawłowska, M. Tudrujek-Zdunek, Krzysztof Tomaszewicz, W. Mazur, Zbigniew Deroń, T. Belicka-Wdowik, Barbara Baka-Ćwierz, I. Buczyńska, Krzysztof Simon, A. Piekarska, J. Białkowska-Warzecha, B. Lorenc, R. Krygier, A. Staniaszek, J. Klapaczyński, J. Citko, Ł. Socha, Marta Wawrzynowicz-Syczewska, Ł. Laurans, Robert Flisiak. Interferon free therapy with and without ribavirin for genotype 1 HCV cirrhotic patients in the real world experience. *Hepatitis Monthly* 2018; 18, 8: e80761

IF₂₀₁₈-1,578; MNiSW-20

22: Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancoriené L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičić M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. *Lancet Gastroenterol Hepatol.* 2018;3(2):125-133

IF₂₀₁₈-12,856; MNiSW-5

Prace kazuistyczne

1: Szulżyk T, Szynaka B, **Lapinski TW**. Late-onset cholestasis of pregnancy: Diagnostic challenges. *Medicine and Medical Sciences* 6(2): 022-025, February, 2018.

Książki

1: Łapiński TW. "The importance of H. pylori infection in liver diseases" in "Helicobacter pylori." IntechOpen, London, 2018 [Epub Ahead of Print]

2: Panasiuk A. Choroby infekcyjne przewodu pokarmowego. PZWL, Warszawa 2018

Z autorstwem w appendixie

1: Razavi-Scheerer D, **Flisiak R**..... [196 Polaris Observatory Collaborators]. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol.* 2018;3(6):383-403.

2: Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; ... **Flisiak R** [Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group – 815 collaborators]. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. *J Int AIDS Soc.* 2018;21(3).

3: Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren JD; ... **Flisiak R** [EuroSIDA study group, 158 collaborators]. Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. *HIV Med.* 2018;19(5):324-338.

4: Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A, Fätkenheuer G, Gatell Artigas JM, Karpov I, Kuznetsova A, Kyselyova G, Mozer-Lisewska I, Mulcahy F, Ragone L, Scherrer A, Uzdaviniene V, Vandekerckhove L, Vannappagari V, Ostergaard L, Mocroft A; ... **Flisiak R** [EuroSIDA study group, 164 collaborators]. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. *HIV Med.* 2018;19(4):252-260.